Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
116 hedge funds and large institutions have $596M invested in Aerie Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 40 reducing their positions, and 18 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
47% more call options, than puts
Call options by funds: $3.53M | Put options by funds: $2.4M
36% more capital invested
Capital invested by funds: $437M → $596M (+$159M)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
1% more funds holding
Funds holding: 115 → 116 (+1)
10% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$11.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$7.6M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$3.65M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.55M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$16.8M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$3.92M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.55M |
| 4 |
Barclays
London,
United Kingdom
|
-$3.39M |
| 5 |
WC
Weatherbie Capital
Boston,
Massachusetts
|
-$3M |
AERI Hedge Fund Activity: Q4 2015 in Review
116 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2015, worth a combined $596M — up 36% from $437M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AERI positions and 18 closed out — a net gain of 1 holder — while 36 added to existing stakes and 40 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $11.6M. The largest seller was Millennium Management, cutting an estimated $16.8M.
- 116 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2015, up from 115 in Q3 2015.
- Funds reported $596M of Aerie Pharmaceuticals stock for Q4 2015, up 36% quarter-over-quarter.
- 19 funds opened new Aerie Pharmaceuticals positions in Q4 2015 and 18 closed out, a net change of +1 holder.
- The largest Aerie Pharmaceuticals buyer in Q4 2015 was AllianceBernstein, an estimated $11.6M added.
- The largest Aerie Pharmaceuticals seller in Q4 2015 was Millennium Management, an estimated $16.8M sold.
Based on aggregated 13F filings for Q4 2015.